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Abstract
Background: Tumor necrosis factor alpha (TNFα) is implicated in a wide variety of pathological
and physiological processes, including chronic inflammatory conditions, coronary artery disease,
diabetes, obesity, and cachexia. Transgenic mice expressing human TNFα (hTNFα) have previously
been described as a model for progressive rheumatoid arthritis. In this report, we describe
extensive characterization of an hTNFα transgenic mouse line.
Results: In addition to arthritis, these hTNFα transgenic mice demonstrated major alterations in
body composition, metabolic rate, leptin levels, response to a high-fat diet, bone mineral density
and content, impaired fertility and male sexual function. Many phenotypes displayed an earlier onset
and a higher degree of severity in males, pointing towards a significant degree of sexual dimorphism
in response to deregulated expression of TNFα.
Conclusion: These results highlight the potential usefulness of this transgenic model as a resource
for studying the progressive effects of constitutively expressed low levels of circulating TNFα, a
condition mimicking that observed in a number of human pathological conditions.
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Background
Increased production of the proinflammatory cytokine
TNFα has been implicated in a number of human diseases
involving inflammation such as autoimmune disorders,
vascular disease and a number of cancers [1]. Most nota-
bly, aberrant expression of the TNFα gene is associated
with rheumatoid arthritis (RA) in both humans and ani-
mal models [2-5]. In addition to the inflammatory com-
ponent of RA, rheumatoid cachexia is characterized by
reduced body weight, increased metabolic rate and
restricted motor activity and also correlates with increased
circulating TNFα levels [6]. Interestingly, TNFα is not only
expressed in macrophages, lymphocytes, neutrophils,
endothelial cells, keratinocytes and fibroblasts [7] but is
also expressed in adipose tissue and is elevated in a
number of experimental obesity models [8-11] and obese
humans [12,13]. The pleiotropic actions of this cytokine
have stimulated interest in animal models involving
genetic manipulation of TNFα itself and components of
its cellular signaling pathway.
Inactivation of the endogenous TNFα gene and its two
cognate receptors have demonstrated its role in inflamma-
tion as well as obesity [14,15]. Transgenic mice expressing
the TNFα gene under the control of various regulatory
sequences have been used as models for RA as well as in
vivo models to study wasting, ischemia, and lymphoid
abnormalities [5,16-18]. Transgenic mice expressing a
non-cleavable membrane bound TNFα have reduced adi-
pose mass [19] and cardiac-specific overexpression of
TNFα in mice results in cardiomyopathy [20]. The pleio-
tropic effects observed in genetic modifications of this
cytokine  in vivo therefore confirm the observations in
humans and support the use of mutant mice as models for
human diseases where a TNFα role has been described. A
comprehensive phenotypic characterization of deregu-
lated expression of TNFα would thus help inform investi-
gators in their decision to use this specific animal model.
Our objective in this series of experiments was to deter-
mine the effects of deregulated hTNFα expression at low
circulating levels on a broad range of murine physiologi-
cal and behavioral measures. To achieve this goal, we
comprehensively screened the hTNFα mice using sequen-
tial bioassays encompassing multiple physiological sys-
tems on the same groups of mice. A comprehensive
phenotypic characterization of genetically-modified ani-
mals is limited by the time and expense in the selective
breeding required to generate subjects for a large number
of assays. To address this issue we have designed a serial
phenotyping procedure used here that requires signifi-
cantly fewer animals. By using such an approach, we were
able to conduct a large number of tests in a relatively short
period of time and used significantly fewer subjects than
would be used in a study limited to experimentally naïve
subjects. We have confidence that the results are reliable
because we validated the order of these tests in wild-type
animals by comparing data obtained by the serial proto-
col to data obtained in experimentally naïve subjects of
comparable ages in pilot studies not included in this
study. Because of the serial nature of our experimental
approach, the results from the transgenic mice are relevant
only to the age at which the specific assay was conducted
and results could differ at different ages (e.g., due to the
progressive-age related- deterioration of their health).
We found that in addition to serving as an improved
model for progressive RA, these hTNFα transgenic mice
exhibited numerous phenotypes including decreased
activity, alterations in soft tissue and bone composition,
impaired physical and metabolic responses to a high fat
diet (HFD), increased food intake, markedly decreased
leptin levels, significantly enhanced energy expenditure,
impaired fertility and erectile dysfunction. The results
from this study demonstrate that this transgenic line is a
valuable model for the study of TNFα role in disease pro-
gression in multiple therapeutic areas including metabo-
lism, obesity, bone homeostasis and male sexual health.
Methods
Animals
hTNFα transgenic (TG) and age- and sex-matched
C 5 7 B L 6 / N  w i l d t y p e  ( W T )  m i c e  w e r e  o b t a i n e d  f r o m
Taconic Farms (Hudson, NY, [21]). The hTNFα TG mice
were generated using a construct that contains a 2.8 kb
fragment of the human TNFα gene, including the entire
coding region and promoter, fused to the human β-globin
3' untranslated region (UTR) that replaces the endog-
enous 3'UTR of the human TNFα gene [16]. This TG line
was produced by pronuclear microinjection of B6SJL(F2)
hybrid zygotes. The animals have been backcrossed for
over 10 generations onto the C57BL6/N genetic back-
ground.
Experimental Procedure
Mice were singly housed in a temperature- and humidity-
controlled barrier facility. The mice were maintained on a
12 hr reverse dark/light cycle (lights go off at 11 AM). Ani-
mals had free access to food and water unless indicated
otherwise in protocols for specific bioassays. All experi-
ments were approved by the Xenogen Biosciences Institu-
tional Animal Care and Use Committee.
The assays used in the initial screen are listed in Table 1.
In the following studies mice were used in multiple assays
unless otherwise noted. The order and corresponding ages
of mice for each assay reported here is given in Table 2.
Consecutive assays were always separated by a minimum
of one week. The mice displayed good health based on
gross observations. Assays for which significant differ-BMC Physiology 2007, 7:13 http://www.biomedcentral.com/1472-6793/7/13
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ences between the hTNFα TG mice and WT controls were
observed in the primary screen were repeated on experi-
mentally naive animals of comparable ages to verify the
initial results. The protocols of individual bioassays fol-
low.
Lipopolysaccharide (LPS)-induced Inflammation
The mice were injected intraperitoneally (i.p.) with either
1 or 10 μg lipopolysaccharide (LPS, Sigma-Aldrich, Inc.,
St. Louis, MO) made up in 2 or 20 mg D-galactosamine
(Sigma-Aldrich, Inc), respectively. Mice from the negative
control group were injected with a phosphate buffered
saline (PBS) vehicle alone. All mice were anesthetized
with isofluorane 1.5 hours after injection, and blood was
obtained from a retro-orbital vein. Serum was prepared by
spinning clotted blood for 20 min at 4°C at 1200 × g.
Human and mouse TNFα levels in the serum of the mice
were detected by ELISA according to the manufacturer's
protocol with a lower limit of detection in the mice assay
of 23.4 pg/ml and 0.5 pg/ml in the human form (R&D
Systems, Minneapolis, MN).
Irwin Observational Battery
The mice were acclimated to the procedure room for at
least 30 min prior to beginning the assay. The Irwin test
battery is a modification of the original comprehensive
observational assessment described by Irwin [18]. The
behaviors were evaluated in one of four circumstances: a
viewing jar, an arena, above the arena, or restrained. Forty-
five endpoints were assessed and scored for each mouse.
A description of the scoring for the measures given in
Table 3 are as follows: Grip Strength (None = 0; Slight
grip, semi-effective = 1; Moderate grip, effective = 2; Active
grip, effective = 3; Unusually effective = 4). Wire maneuver
(Active grip with hindlegs = 0; Difficulty to grasp with
hindlegs = 1; Unable to grasp with hindlegs = 2; Unable to
Table 2: Age of mice and order of experiments
Age (weeks) Assay Longitudinal Study
8 LPS challenge
15 Irwin Body Weight (RC)
16 Food Intake Body Weight (RC)
17 Male Fertility Body Weight (RC)
18 Male Sexual Behavior Body Weight (RC)
19 Male Sexual Behavior Body Weight (RC)
20 Male Sexual Behavior Insulin Body Weight (RC)
21 OGTT (pre-HFD) Body Weight (RC)
22 DEXA(pre-HFD & Low Ca) Body Weight (RC)
23 HFD Begins Body Weight (RC)
Body Weight (HFD)
24 Leptin Body Weight (RC)
Body Weight (HFD)
25 Body Weight (RC)
Body Weight (HFD)
26 Body Weight (RC)
Body Weight (HFD)
27 MicroCT OGTT (post-HFD) Body Weight (RC)
Insulin DEXA(post-Low Ca) Body Weight (HFD)
28 DEXA (post HFD) Body Weight (RC)
CLAMS Body Weight (HFD)
29 Insulin Tolerance Test
Table 1: List of bioassays used for characterization in the initial 
screen and result summary
Therapeutic Field Bioassays Phenotype
Cardiovascular, renal 
and bladder function
Bladder function (F) NS
Blood pressure/heart rate (M) ↑(BP)*
Urine chemistry panel (F) NS
CNS and Behavior Irwin test (M,F) ↓***
Cross-therapeutic 
assays
Automated blood chemistry 
panel (M)
NS
Body weight measurements 
(M,F)
NS
Corticosterone (M) ↑*
Immunology and 
Inflammation
DTH (M) NS
FACS analysis (M) ↓*
LPS challenge (M) NS
Monocyte infiltration (F) ↑*
Pulmonary inflammation (F) NS
Wound healing (F) NS
Metabolism and 
Body Composition
DEXA (F) ↓*
Excised bone DEXA (F) ↓**
Food intake (M,F) NS
Food intake on HFD (M) ↑***
Leptin (M,F) ↓**
Metabolic response to HFD (M) ↑**
Physical response to HFD (M) ↓***
Selected muscle weight (F) ↓**
Pain Formalin pain assay (M) NS
Hot-plate assay (F) NS
Sexual health Histopathology of reproductive 
system (M)
NS
Induced erection test (M) ↓*
Male contact sexual behavior 
(M)
↓***
Male fertility (M) ↓***
Testosterone (M) NS
The highest levels of significance among all measures measured in the 
assay are shown by asterisks: * P < 0.05, ** 0.001 < P < 0.01, *** P < 
0.001 and arrows indicate measurements in the TG line increased or 
decreased from WT. No significant difference between genotypes 
(NS), males (M), females (F), delayed-type hypersensitivity (DTH), 
fluorescence-activated cell sorting (FACS), lipopolysaccharide (LPS), 
Dual energy X-ray analysis (DEXA) high fat diet (HFD).BMC Physiology 2007, 7:13 http://www.biomedcentral.com/1472-6793/7/13
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lift hindlegs, falls within seconds = 3 ; Falls immediately =
4). Tail elevation (Dragging = 0; Horizontally extended =
1; Elevated = 2).
Appropriate statistical tests were used to compare the TG
mice to their WT counterparts (Fisher's exact t, Mann-
Whitney U, unpaired t-tests).
Food Intake on Regular Chow
The mice were singly housed in clean cages with one sheet
of Iso-pad bedding (Harlan-Teklad, Indianapolis, IN) and
a weigh boat containing dustless precision pellets (Bio-
Serv, Frenchtown, NJ). They were habituated to this envi-
ronment for 72 hours. At the end of the habituation
period, the mice were placed in new cages containing Iso-
pad bedding and 20 food pellets. The weights of both the
food and the mice were recorded. The experimental phase
lasted 72 hours at which point the remaining food was
recovered and weighed. Food intake was expressed as mg
food consumed/g body weight/24 hours. An unpaired t-
test was used to analyze differences between genotypes.
Leptin
Blood was collected via retro-orbital bleeds from fasted or
freely fed mice. Serum was prepared by spinning clotted
blood for 20 min at 4°C at 1200 × g and frozen at -20°C.
The leptin ELISA was performed according to the manu-
facture's protocol (R&D Systems). An unpaired t-test was
used to analyze differences due to genotype.
Responses to HFD
The HFD challenge used the Western high fat/high carbo-
hydrate diet (42.7 kcal % carbohydrate, 40.3 kcal % fat, 17
kcal % protein, D12079B, Research Diets, Inc., New
Brunswick, NJ). The body weights of the mice were meas-
ured weekly and the following metabolic, anatomical and
behavioral assays were conducted prior to and at the end
of the HFD challenge.
Whole Body Dual Energy X-ray Analysis (DEXA)
On the first day of the HFD the mice were weighed and
their body composition was assessed by DEXA scan. The
analysis was performed on a PIXImus2 X-ray unit (GE
Lunar Corporation, Madison, WI) connected to a compu-
ter equipped with LUNAR PIXImus software. The head
region was excluded from analysis. The following meas-
ures were directly made or calculated by the PIXImus2
software: bone mineral density, bone mineral content,
bone area, tissue area, R soft tissue value (RST – ratio of
attenuation of low energy and high energy beams in soft
tissue), percent fat, and total tissue mass (TTM). Fat mass,
percent of lean and lean mass were calculated manually as
follows:
% Lean = 100 – % Fat
Lean Mass = TTM × (100 – % Fat)
Fat Mass = TTM × % Fat
An unpaired t-test was used to analyze differences
between genotypes for each measure. At the end of the
HFD period final body weights were taken and a post-
HFD DEXA scan was also obtained.
Food Intake on HFD
During week 4 of the HFD food intake measurements
were performed while mice were singly housed in clean
cages on standard corn cob bedding and weighed at the
start of the experimental period, which lasted 72 hours. At
the beginning of the assay, mice were given approximately
15 grams of pre-weighed high-fat food pellets. At the end
of the experiment the remaining food was recovered and
weighed. Food intake was expressed as the mg food con-
sumed/g body weight/24 hours. An unpaired t-test was
used to analyze differences due to genotype.
MicroCT Analysis
During week 4 of the HFD the sizes of regional fat depots
were determined by microCT analysis. Images of anesthe-
tized mice were obtained using a commercially available
microCT system (MicroCAT®, ImTek Inc. Oak Ridge, TN)
with a high-resolution CCD/phosphor screen detector.
Images were acquired with the X-ray biased at 40 kVp and
400 μA using a 0.5 mm aluminum filter. Each scan con-
sisted of 196 individual projections with an exposure time
of 320 ms/projection. Image reconstruction, whereby the
196 projections acquired in the scan were manipulated to
produce two-dimensional cross sectional images of the
mouse, was performed using the MicroCAT® Reconstruc-
tion, Visualization, and Analysis Software (ImTek Inc.,
Table 3: Phenotypes in the Irwin observational panel
Observation Genotype Males Females
Body weight (g) WT 31.5 ± 18.8 20.3 ± 0.9
TG 25.5 ± 1.7* 22.2 ± 0.9
Body length (mm) WT 92.8 ± 0.9 86.6 ± 0.5
TG 89.4 ± 1.0* 87.8 ± 1.1
Grip strength (score 0–4) WT 2.4 ± 0.2 1.0 ± 0
TG 0.8 ± 0.2** 1.6 ± 0.2
Wire maneuver (score 0–4) WT 1.4 ± 0.2 2.8 ± 0.5
TG 4.0 ± 0*** 2.0 ± 0.6
Tail elevation (score 0–2) WT 2.0 ± 0 1.4 ± 0.2
TG 1.2 ± 0.2* 1.2 ± 0.2
Values represent the mean ± SEM n = 5 mice for each sex/genotype 
combination. The level of significance is shown by asterisks: * P < 0.05, 
** 0.001 <P < 0.01, *** P < 0.001. For scoring description see Methods 
section for Irwin observational panel.BMC Physiology 2007, 7:13 http://www.biomedcentral.com/1472-6793/7/13
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Oak Ridge, TN). Slices were selected spanning the region
between vertebral landmarks S4-S3 and L1–T13 using a
90° scout radiograph projection. Two-dimensional slices
were reconstructed using a Shepp-Logan filtered back pro-
jection algorithm on a 256 × 256-pixel grid where the
pixel size is 260 × 260 μm and the slice thickness is 1.6
mm. After reconstruction, the 2D-transaxial slice images
were exported in *.bmp format for image analysis. Image
analysis and volumetric fat calculations for renal/retro-
peritoneal, mesenteric, epididymal and inguinal depots
were accomplished in 3D-Doctor (Able Software Corp.,
Lexington, MA). An unpaired t-test was used to analyze
differences between mice of different genotypes for each
parameter.
Metabolic Responses to HFD
Mice fed the HFD for five weeks and mice maintained on
regular low fat chow (rodent Purina diet #5053, Fisher
Feeds, Bound Brook, NJ) were fasted overnight and then
bled from the retro-orbital sinuses. The samples were left
to coagulate and then centrifuged at 4°C to isolate the
serum. The serum was immediately frozen and stored at -
80°C. The frozen serum samples collected from all of the
mice before and at the end of the HFD were defrosted and
analyzed in parallel for serum insulin by ELISA (UltraSen-
sitive Mouse Insulin ELISA; ALPCO, Salem, NH) accord-
ing to the manufacturer recommendations. To assess
glucose tolerance, mice maintained on regular chow or
the same mice after feeding on the HFD for 5 weeks were
fasted for 16 – 20 hrs prior to the oral glucose tolerance
test (OGTT). The animals were weighed immediately
before the test and then the baseline serum glucose level
was measured in a drop of blood obtained from a cut at
the tip of the tail. The glucose levels were measured by a
Glucometer Elite (Bayer, Leverkusen, Germany). The mice
then received 1 g/kg body weight of 100 mg/ml glucose
solution (Sigma, St. Louis, MO) in sterile water delivered
by oral gavage. At 30, 60 and 120 min after the gavage,
glucose concentration was measured as described above.
The insulin tolerance test (ITT) was performed on ad libi-
tum fed males during the 7th week of the HFD with
human regular insulin at a dose of 75 U/kg injected i.p.
Body weights, OGTT and ITT results were analyzed by
two-way ANOVA. All other endpoints were also analyzed
using an unpaired t-test to identify differences due to gen-
otype.
Comprehensive Laboratory Animal Monitoring System
Mice fed the HFD for six weeks and mice maintained on
the regular chow diet were assessed for 48 hours in the
Comprehensive Laboratory Animal Monitoring System
(CLAMS, Columbus Instruments, Columbus, Ohio).
Measurements included oxygen consumption (VO2), car-
bon dioxide production (VCO2), respiratory exchange
ratio (RER, calculated), calculated heat production, total
horizontal activity, ambulatory activity, non-ambulatory
horizontal activity, vertical (rearing) activity and licking
frequency. Results were averaged by photoperiod and ana-
lyzed by two-way ANOVA. For the heat production, oxy-
gen consumption and carbon dioxide production
endpoints, weight change was used as a covariate in the
ANCOVA.
Low Calcium Dietary Challenge
Following a baseline DEXA scan of bone composition, the
mice were maintained on diet # D02040301 from
Research Diets (New Brunswick, NJ) for a period of four
weeks. This diet contains 0.01% calcium. After four weeks
on the diet a second DEXA scan was performed. The per-
cent change from baseline was calculated for each end-
point and an unpaired t-test was used to analyze
differences between mice of different genotypes for each
time point.
Male Fertility
On the first day of testing, CD1 females were introduced
to the experimental males before the beginning of the
dark phase of the light/dark cycle and left with males for
one week. Vaginal mating plugs were checked daily at the
end of the light phase. On day 8 the pairs were separated.
Females were individually housed and allowed to deliver
litters. The number of litters and litter size were deter-
mined for males of each genotype.
Male Contact Sexual Behavior
This assay was performed on the same male mice used in
the Male Fertility assay. Prior to testing, the males were
trained twice per week for two consecutive weeks. 8–10
Week old ovariectomized ICR female mice (Taconic
Farms, Hudson, NY) implanted with a 2.5 mg 17-β-estra-
diol pellet (Innovative Research of America, Sarasota, FL)
and injected with progesterone (Sigma-Aldrich, Inc) (500
μg in 0.2 ml of sesame oil 5 hours prior to the start of the
experiment) were introduced to the cages of experimental
males 1 hr after the onset of the dark phase for 4 hrs. After
each training session females were observed for copulative
plugs. Thirty minutes prior to the testing session the males
were evaluated in the induced erection test as described
below. Then the ovariectomized females supplemented
with estrogen and progesterone were introduced to the
male cages. The cages were placed in testing video cabinets
(Noldus Information Technology, Wageningen, Nether-
lands) and sessions were digitally recorded for 45 min
(Numeriscope™, Viewpoint, Champagne, France). The
testing sessions were analyzed by a trained operator blind
to the genotype using Observer software (Noldus Infor-
mation Technology). The total number of mounts,
intromissions and ejaculations were determined for every
male. Latencies to the first mount and to the first intromis-BMC Physiology 2007, 7:13 http://www.biomedcentral.com/1472-6793/7/13
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sion (from the beginning of the experiment) and latency
to ejaculation from the first mount were also determined.
Induced Erection Test
The testing was performed during the dark phase of the
light cycle under red light. The male mice were held tightly
in supine position. The penile sheath was retracted and
gentle pressure was applied to the mouse abdomen for
10–15 s. The occurrence of penile erection was recorded.
Erections were scored as present (1) or absent (0).
Between group differences were analyzed by Chi-square
test.
Histolopathological Evaluation of the Reproductive 
Tissues
The reproductive tissues from two TG and two WT male
mice were fixed in 4% formalin and sent without geno-
type identification to the Pathology Associates, a Charles
River Company (Wilmington, MA) for histopathological
evaluation. Testes were trimmed, embedded in glycol
methacrylate (GMA), and stained with PAS/hematoxylin.
The epididymides, prostates, seminal vesicles and penises
were trimmed, embedded in paraffin, sectioned at
approximately 5 microns, and stained with hematoxylin
and eosin. Tissues were examined microscopically by a
certified veterinary pathologist.
Excised Bone DEXA Analysis
The animals were euthanized and the right femurs and the
L1 – L6 region of the spine were excised from the bodies
and scanned on PIXImus2 as described in the manufac-
turer's manual. The region of interest was adjusted to fit
the excised bone only. For both excised femur and L1 – L6
spine, the following measurements were made: bone min-
eral density, bone mineral content, bone area, bone
length and width. An unpaired t-test was used to analyze
differences between mice of different genotypes for each
measure.
Staticstical Analysis
Statistical analysis was performed for each assay as indi-
cated. Two-factor ANOVAs (with or without repeated
measures) were performed using the SPSS statistical pack-
age (SPSS Inc., Chicago, IL). T-tests (paired or unpaired)
were performed using Graphpad Prism (San Diego, CA)
or Microsoft Excel. The data were assessed for outliers
defined as two or more standard deviations from the
mean and values exceeding these parameters were
excluded.
Results
Characterization of Transgene Expression
To characterize the expression and regulation of the
hTNFα transgene, we measured circulating hTNFα in
unchallenged mice and tested it's inducibility relative to
the endogenous mouse TNFα gene using increasing doses
of LPS. Sera from 5 TG and 5 WT males were assayed with
two ELISA systems specific for human or murine TNFα
protein respectively, after i.p. injection with vehicle (PBS),
1 μg LPS or 10 μg LPS. In the TG mice, hTNFα protein was
detectable at low levels in all treatment groups and did
not significantly change following treatment with the two
LPS doses (Figure 1A). As expected, mouse TNFα levels in
TG and WT mice injected with PBS were undetectable but
we observed a robust dose-dependent induction of the
murine TNFα gene in both the TG and WT animals fol-
lowing LPS treatment (Figure 1B). Additionally, the
hTNFα transgene appeared to have no impact on endog-
enous TNFα production since no effect of genotype was
Serum TNFα Levels After IP LPS Challenge Figure 1
Serum TNFα Levels After IP LPS Challenge. LPS did 
not significantly alter expression of the transgene but dose-
dependently increased endogenous TNFα in WT and TG 
mice similarly. WT (open bars) and TG mice (closed bars) 
were injected with the indicated doses of LPS (μg/mouse) as 
shown on the X-axis. (A) Human and (B) mouse TNFα levels 
were measured using ELISA assays. Data are presented as 
means ± SEM, n = 5 for each genotype and dose combina-
tion. ND – non-detectable.
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detected by two-factor ANOVA. In a separate experiment
we compared hTNFα levels in untreated male and female
TG mice with WT littermates as negative controls. Very
low levels of circulating hTNFα, which were only detecta-
ble with a highly sensitive assay, were measured in the TG
mice (males 5.83 ± 0.58 pg/ml; females 6.51 ± 0.48 pg/
ml, n = 5 for each sex/genotype combination). hTNFα was
undetectable in the WT mice.
Irwin Observational Panel
The Irwin Observational Panel was performed on mice at
15 weeks of age. This test encompasses basic observations
in four categories: physical characteristics, autonomic
responses, behavioral responses, and neurological
responses [22]. The male TG mice differed significantly
from WT mice in 5 out of 45 observations (Table 3).
Assessment of physical characteristics found that body
weight and body length were decreased in male hTNFα
mice. Results in three tests designed to measure neurolog-
ical responses related to muscle tone differed between the
male TG and WT mice: hTNFα TG males exhibited
reduced grip strength, were unable to grasp a wire in the
wire maneuver test and displayed less elevated tail posi-
tions than the WT males (Table 3). Interestingly, the
female TG mice at this age did not differ from their WT
counterparts in any observation (Table 3). The sexual
dimorphism seen in the Irwin test suggests that despite
possessing similar levels of circulating hTNFα, the female
TNFα mice had a milder phenotype than age-matched
males, which is consistent with our observation that they
tend to manifest arthritic symptoms later than the male
TG animals (data not shown).
Energy Homeostasis on Regular Chow
Food Intake, Body Weight and Soft Tissue Composition
Food intake was studied in 16 week old mice and the
amount of food consumed per gram of body weight per
24 hours was calculated. There was no statistically signifi-
cant difference in the amount of food consumed by the
hTNFα TG mice as compared to the WT controls when
both sexes were combined (WT: 105 ± 14 mg/gm BW/24
hrs vs TG: 99 ± 9 mg/gm BW/24 hrs) and no difference
when results from males (WT: 77 ± 5 mg/gm BW/24 hrs
vs TG: 88.2 ± 12 mg/gm BW/24 hrs) or females (WT:129
± 20 mg/gm BW/24 hrs vs TG:110 ± 12 mg/gm BW/24
hrs) were analyzed separately (n = 5 for each sex/genotype
combination). Similarly, no difference in total food
intake was observed between genotypes when the total
amount of food consumed per day was assessed without
normalizing to body weight (data not shown). To estab-
lish a longitudinal body weight profile of the TG mice
weights of 4 males and 6 females of each genotype main-
tained on regular chow were taken at four intervals
between 15 and 28 weeks of age. Consistent with body
weight results from the Irwin test we found that the TG
males were significantly lighter than WT controls
(ANOVA  F1,38 = 33.73, P  < 0.0001) over the 13 week
period (Figure 2A). These data suggest a change in energy
homeostasis since the differences in body weights
between the TG and WT mice were not due to differences
in food consumption. The body weights of females
between 15 to 28 weeks of age did not significantly differ
by genotype but the interaction between time and geno-
type was significant (ANOVA F5,69 = 6.74, P < 0.0001),
indicating that WT females gained weight over the period
measured but TG females did not (Figure 2B).
Consistent with the difference in body weights between
the TG and WT males, DEXA analysis of 22-week-old TG
male mice maintained on regular chow showed signifi-
Body Weights Figure 2
Body Weights. TG males were significantly lighter than 
WT males and the weight of TG females did not increase 
over time like WT females (A) Weights of male WT (open 
squares n = 4) and TG (black triangles n = 4) mice between 
15 and 26 weeks of age. (B) Weights of female WT (open 
squares n = 6) and TG (black triangles n = 6) mice between 
15 and 28 weeks of age. Results represent the mean ± SEM. 
The level of significance is shown by asterisks: * P < 0.05, ** 
0.001 <P < 0.01, *** P < 0.001 in the post-hoc analysis.
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cant reductions in total tissue mass, total tissue area, fat
mass, and lean mass (Table 4). Fat mass was 50% lower in
the TG group and lean mass was reduced by 14%. The TG
mice were relatively leaner than WTs as demonstrated by
a significant increase in percent lean values. Overall, these
results demonstrate that both fat mass and lean mass were
decreased in the TG males, but that fat mass was decreased
more than lean mass. In contrast, 22-week-old hTNFα
females on regular chow did not exhibit significant differ-
ences in the relative proportions of fat and lean mass as
determined by DEXA analysis relative to the WT controls
(Table 4). Both the results of the soft tissue body compo-
sition analysis, and the later divergence in body weight in
the females, suggest a sexual dimorphism in the response
to similar levels of circulating hTNFα, consistent with the
delayed onset of arthritis in females compared to males
(data not shown).
Circulating leptin
Leptin levels were measured in serum from 25 week-old
fasted and 26 week old ad libitum fed males maintained
on regular chow. Both fasted and fed blood leptin levels
were significantly lower in TG males compared to WT ani-
mals (WT fasted: 2.663 ± 0.590 ng/ml [n = 7] vs. TG
fasted: 0.019 ± 0.012 ng/ml [n = 7], P = 0.004; WT fed:
5.997 ± 0.758 ng/ml [n = 7] vs. TG fed: 1.015 ± 0.270 ng/
ml [n = 6], P = 0.0004). Leptin levels usually correlate
closely with the amount of white adipose tissue. However,
in the hTNFα TG males leptin levels appeared dispropor-
tionately low as they were undetectable in fasted mice
while in the fed state were reduced six-fold, but fat mass
in the TG was reduced only two-fold. Twenty six week old
TG females also showed a marked decrease in leptin levels
compared to the WT controls; leptin levels in fasted WT
females were 1.356 ± 0.385 ng/ml [n = 6] but were 0.144
± 0.089 ng/ml [n = 6] in TG females (P = 0.028). These
data demonstrate a striking dissociation between fat mass
and leptin secretion since TG females had unchanged fat
mass compared to WT but exhibited an almost ten-fold
reduction in circulating leptin levels. Additionally, the
food-intake measurements in mice fed regular diet did not
detect any difference between genotypes despite signifi-
cantly lower leptin levels. As leptin was measured nine to
ten weeks after the food intake experiment we cannot rule
out the possibility that the reduced serum leptin levels
were a manifestation of a progressive decrease in body
weight of the TG mice.
Energy Homeostasis on HFD
Food intake, weight gain and soft tissue composition
The HFD challenge began when the mice were 23 weeks
old. Although there were no differences between geno-
types on the regular chow diet, a clear difference in food
intake was observed between the WT and TG males meas-
ured during the fourth week of the HFD (WT: 94.6 ± 4.8
mg/gm BW/24 hrs [n = 7] vs TG: 122.2 ± 11 mg/gm BW/
24 hrs [n = 6]; P = 0.0363). In addition to the TG males
being lighter and leaner before the HFD challenge, they
also failed to significantly increase their body weight in
response to the HFD while WT male body weights
increased 22.9% in five weeks (Figure 3). The significant
differences in weight gain was evidenced by an interaction
between genotype and time detected by ANOVA (F5,45 =
38.0,  P  < 0.0001). DEXA analysis demonstrated that
although fat mass was slightly increased in the hTNFα TG
mice following the dietary challenge, they remained
markedly leaner than the WT group (Table 4).
Table 4: Soft tissue composition and body weight
Parameter Genotype Females Males
RC RC HFD
Tissue area WT 22.99 ± 0.30 (n = 7) 27.34 ± 0.59 (n = 8) 31.70 ± 0.67 (n = 8)
TG 21.96 ± 0.51 (n = 5) 24.66 ± 0.33**(n = 7) 24.87 ± 0.49*** (n = 5)
Total tissue mass WT 22.18 ± 0.57 32.00 ± 1.22 40.46 ± 1.48
TG 20.92 ± 0.69 26.09 ± 0.53** 26.63 ± 0.97***
Fat mass WT 2.47 ± 0.22 6.37 ± 0.8 15.33 ± 1.05
TG 1.97 ± 0.12 3.20 ± 0.26** 5.45 ± 0.68***
Lean mass WT 19.71 ± 0.36 25.63 ± 0.59 25.13 ± 0.47
TG 18.95 ± 0.57 22.89 ± 0.35** 21.81 ± 0.35***
% fat WT 11.15 ± 0.72 19.53 ± 1.67 37.57 ± 1.37
TG 9.39 ± 0.28 12.20 ± 0.82** 20.08 ± 1.91***
% lean WT 88.85 ± 0.72 80.47 ± 1.67 62.43 ± 1.37
TG 90.61 ± 0.28 87.80 ± 0.82** 79.92 ± 1.91***
Body weight WT 24.16 ± 1.02 32.19 ± 1.15 40.17 ± 1.46
TG 22.01 ± 0.75 26.46 ± 0.50** 26.72 ± 0.91***
Values represent the mean ± SEM. RC is regular chow and HFD is high fat diet. The level of significance is shown by asterisks: * P < 0.05, ** 0.001 
<P < 0.01, *** P < 0.001.BMC Physiology 2007, 7:13 http://www.biomedcentral.com/1472-6793/7/13
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Regional Adipose Distribution
To extend the observation that total adipose tissue was sig-
nificantly decreased in the TG males, microCT analysis
was used to examine individual adipose depots during the
fourth week of the HFD experiment. Figure 4A shows the
volumes of the inguinal, epididymal, renal and
mesenteric fat depots normalized by body weight. Con-
sistent with the results from the DEXA scan (Table 4), the
TG males showed significant decreases in all adipose
depots examined. To normalize adipose distribution, the
sum of all four depots was used. Normalized adipose vol-
umes for each individual depot were expressed as percent
of the total fat. The normalized volumes of regional fat
depots, shown in Figure 4B, demonstrate that the TG mice
had a relative deficit in the percentage of fat stored in the
renal depot and a trend towards decreased fat in the
mesenteric depot (P < 0.1). Trends reflecting an increase
in the percent of fat located in the inguinal and epididy-
mal depots of the TG mice were also observed (P < 0.1).
As the renal and mesenteric regions normally exhibit the
largest increases in size relative to the other depots in
response to a high-fat diet, the differences between the WT
and TG mice most likely reflect an impaired ability of the
TG males to increase adipose volume in response to the
HFD, rather than a direct role of TNFα in fat redistribu-
tion.
OGTT, Insulin Levels and Insulin Sensitivity
Prior to the HFD challenge, baseline measurements of
glucose disposal assessed by an OGTT were measured in
21 week old mice and the OGTT was repeated at the end
of the HFD challenge at 27 weeks of age. WT and TG
groups did not differ in their ability to clear a glucose load
before the HFD challenge (Figure 5A) but the TG mice
showed a markedly lower glucose excursion compared to
the WT group following 6 weeks on the HFD as deter-
mined by a main effect of genotype in a two-factor
ANOVA (F1,9 = 10.52, P = 0.01) (Figure 5B).
MicroCT Analysis of Regional Adipose Distribution Figure 4
MicroCT Analysis of Regional Adipose Distribution. 
TG males failed to increase regional fat depot volumes fol-
lowing a HFD. (A) The amount of fat in cubic millimeters 
quantitated by microCT analysis and normalized by body 
weight is shown for WT males by open bars and TG males by 
closed bars. The individual depots are shown below the X-
axis. (B) The percent of fat distributed in each adipose depot 
relative to total adipose tissue quantitated by microCT is 
shown for WT males by open bars and TG males by closed 
bars. The individual depots are shown below the X-axis. 
Results represent the mean ± SEM, WT n = 6 and TG n = 7. 
t indicates P < 0.10, * P < 0.05, ** 0.001 <P < 0.01, *** P < 
0.001.
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Weight Gain in Response to a HFD Figure 3
Weight Gain in Response to a HFD. TG males failed to 
increase body weight on a HFD. Weekly body weight meas-
urements for WT (open squares n = 8) and TG (closed trian-
gles n = 8) males taken over the course of five weeks on the 
HFD. Results represent the mean ± SEM. The level of signifi-
cance is shown by asterisks: * P < 0.05, ** 0.001 <P < 0.01, 
*** P < 0.001.BMC Physiology 2007, 7:13 http://www.biomedcentral.com/1472-6793/7/13
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Fasting insulin levels were determined in serum samples
collected pre and post HFD challenge at 20 and 27 weeks
of age, respectively. There were no detectable differences
in fasting insulin levels between the two groups prior to
the HFD challenge but following the diet WT insulin lev-
els significantly increased while there was no significant
change in insulin levels in the TG males (Figure 5C). A
direct measurement of insulin tolerance was performed
after 7 weeks on the HFD when the mice were 29 weeks
old. The WT mice failed to show a significant decrease in
circulating glucose levels at all time points tested in
response to an i.p. injection of insulin, demonstrating
diet-induced insulin-resistance (Figure 5D). In contrast,
the TG males were extremely sensitive to insulin with a
pronounced reduction in glucose levels at all time points
evaluated up to two hours following insulin treatment,
resulting in both a main effect of genotype (F1,10 = 10.48,
P = 0.009) and a significant interaction between genotype
and time (F3,30 = 13.72, P < 0.0001) in the ANOVA analy-
sis (Figure 5D). These results confirmed that the TG mice
had higher insulin sensitivity compared to the WT con-
trols following a HFD challenge.
Metabolic Rate and Physical Activity
The observation that TG males increased their food intake
on the HFD but failed to increase their body weight and
fat mass suggested that the metabolic rate and/or activity
levels of the TG males were altered. To determine this we
Glucose Disposal, Insulin Levels and Insulin Sensitivity Figure 5
Glucose Disposal, Insulin Levels and Insulin Sensitivity. TG mice failed to develop insulin resistance on a HFD. In A, B, 
and D, WT data is shown as open squares and TG data by closed triangles. (A) OGTT performed on fasted males prior to the 
start of the HFD showed no significant difference between genotypes (WT n = 7 and TG n = 8). (B) OGTT performed on 
fasted males following the HFD challenge showed decreased glucose excursion by TG mice (WT n = 7 and TG n = 5). (C) 
Serum insulin levels in fasted males measured from samples acquired pre and post HFD challenge, WT values are shown by 
open bars (n = 8) and TG by closed bars (n = 7). (D) Results from the insulin tolerance test performed after the HFD chal-
lenge. Insulin levels increased in response to 2 weeks of HFD challenge in WT (n = 7) but not TG (n = 5) mice. All results rep-
resent the mean ± SEM. * indicates P < 0.05, ** indicates P < 0.01 and *** indicates P < 0.001 in post-hoc analysis.
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assessed the physical activity and metabolic rate of the
mice after the sixth week of the HFD, when the mice were
28 weeks old, using indirect calorimetry in the CLAMS
(Table 5). We observed that VO2, VCO2, and heat produc-
tion normalized to body weight were significantly
increased in the TG mice, although RER was not signifi-
cantly different between the two genotypes. Locomotor
activity was markedly suppressed in the hTNFα males
even though their metabolic rate was increased. We also
assessed the metabolic measures and activity of a separate
group of 27 week old TG and WT males maintained on
regular chow. These results showed differences between
the two groups similar to the differences observed in mice
on the HFD (Table 5), ruling out the HFD challenge as the
cause for the observed differences in metabolic rate and
locomotor activity.
Bone Density and Response to a Low Calcium Dietary 
Challenge
DEXA analysis was used to assess bone mineral density
(BMD), bone mineral content (BMC) and bone area in
the TG (n = 7) and WT (n = 8) mice maintained on regular
chow at 22 weeks of age. Significant reductions in BMD
(WT: 0.0477 + 0.0007 vs TG: 0.0428 + 0.0005, P < 0.001)
and BMC (WT: 0.425 + 0.0075 vs TG: 0.378 + 0.0053, P <
0.001) were observed in TG males, although bone area
was not significantly reduced. In 22-week-old WT (n = 7)
and TG (n = 8) females, BMD (WT: 0.0479 + 0.0002 vs
TG: 0.0442 + 0.0006, P < 0.001) and BMC (WT=: 0.4192
+ 0.0052 vs TG: 0.383 + 0.0058, P < 0.01) measured in the
whole animal were also significantly decreased. In addi-
tion, excised femurs and lumbar vertebrae (L1 to L6) from
the same females were examined using DEXA. BMC and
bone area were significantly reduced in the TG femurs and
both BMD and BMC were markedly lower in the excised
vertebrae from TG females relative to WT controls (data
not shown). In order to further explore this phenotype in
females, a low calcium dietary challenge was used. Ini-
tially, TG and WT mice were scanned by DEXA to establish
baseline values for BMD and BMC. The mice were then
fed a diet containing only 1.25% of the calcium available
in regular chow for four weeks. A second DEXA scan was
performed on 27 week old females and the changes in
BMD, BMC and bone area were compared. The BMD and
BMC of TG females were significantly lower than the WT
controls prior to the restriction in dietary calcium as
shown above and these differences were exacerbated in
response to the diet (Figure 6A–C). TG females were more
susceptible to loss of BMD, BMC and bone area compared
to WT mice when measured as the percent change from
baseline.
Male sexual behavior and fertility
Male sexual behavior was tested at 17 weeks of age in
which the number of males that mounted receptive
females, performed intromissions and ejaculated were
compared between genotypes. Significantly fewer TG than
WT males mounted females during the 45 min test and
the number of TG males that performed intromissions
was also significantly lower compared to the controls
(Table 6). The number of mounts and intromissions per
performing male, as well as latencies to the first mount
and intromission were similar in the TG and WT groups
(data not shown).
Penile erection was tested in two separate experiments
comparing TG and WT males in the induced erection test.
In the first experiment significantly fewer TG males dis-
played an erection compared to WTs (Chi-square, P =
0.005). In the second study there was still a difference but
it did not reach statistical significance (Chi-square, P =
0.06, Table 6).
A significantly smaller number of the TG males sired preg-
nancies after one week with CD1 females (Table 6). All
pregnant females gave birth to live litters. There was no
effect of the transgene on the litter size detected at this age
(12.75 ± 0.9, n = 4, TG; 12.67 ± 0.4, n = 9, WT). The anal-
Table 5: Metabolic measures and activity measured in the CLAMS
Parameter WT (n = 8) TG (n = 6) TG Percent of WT WT (n = 7) TG (n = 5) TG Percent of WT
HFD HFD HFD RC RC RC
Oxygen consumption ml/kg/hr 2989 ± 93 3823 ± 110 128*** 2770 ± 106 3454 ± 197 125**
Carbon dioxide production ml/
kg/hr
2336 ± 114 2932 ± 124 124** 2510 ± 160 2985 ± 220 118*
Heat production Kcal/g 0.014 ± 0.001 0.018 ± 0.001 127*** 0.014 ± 0.001 0.017 ± 0.001 123**
Respiratory exchange ratio 0.789 ± 0.015 0.764 ± 0.016 97 0.902 ± 0.036 0.856 ± 0.025 95
Ambulatory activity beam 
breaks/hr
1220 ± 65 458 ± 102 36** 1839 ± 283 448 ± 72 25***
Vertical activity beam breaks/hr 2124 ± 91 468 ± 133 21*** 2550 ± 289 603 ± 166 22***
Values represent the mean ± SEM. The level of significance is shown by asterisks: * P < 0.05, ** 0.001 <P < 0.01, *** P < 0.001. HFD – high fat diet; 
RC – regular chow; TG percent of WT – measures of TG mice expressed as percent of the measures from the WT group.BMC Physiology 2007, 7:13 http://www.biomedcentral.com/1472-6793/7/13
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ysis of hematoxylin/eosin stained sections of the prostate,
epididymis, seminal vesicles and penises, in addition to
examination of PAS/hematoxylin stained sections of tes-
tes from two TG and two WT mice, did not reveal any dif-
ferences due to the presence of the transgene (data not
shown).
Discussion
The TG mice reported here develop progressive arthritis
[21] similar to previously described transgenic lines gen-
erated with this construct [16] but do so at a later age, con-
sistent with the lower levels of circulating TNFα than in
the lines reported earlier [18,23] and more closely resem-
bling the progression of RA in humans. We generated sev-
eral lines of transgenic mice with this construct and
although all of the lines had an arthritis phenotype we
chose this line for a more thorough characterization
because of its slower onset of the arthritis phenotype. In
the generation of transgenic mice the integration site can
be a factor in observed phenotypes because there is no
control over the copy-number of transgenes that integrate
and possible direct or indirect influences from the integra-
tion (unintended mutations of other genes or cis-genetic
effects influencing expression). Thus, although the expres-
sion level in this line has utility as a model for human RA
progression, a direct comparison between multiple lines
with similar, low levels of expression is required to for-
mally prove that the phenotypes observed here are due to
the deregulated TNFα expression. Nonetheless, in addi-
tion to RA found in this line as well as previously pub-
lished lines, the reduced body weight, increased
metabolic rate and restricted motor activity correlate well
with similar findings described in humans with rheuma-
toid cachexia [6]. Bone loss, which has also been previ-
ously described [23] was documented in the line
described here. Lastly, the male TG mice have some sexual
behavior dysfunctions that could be attributable to mod-
erate disease progression of RA but the low scores for
induced erection tests suggest that the sexual behavior
phenotypes may be due to multiple causes. Our approach
Table 6: Number of hTNFα and WT mice performing male 
sexual behaviors
Parameter TG WT P-value
Present Absent Present Absent
Mounting 
Behavior
751 2 0 0 . 0 1 2
Intromission 2 10 9 3 0.041
Induced erection 
(1)
781 4 1 0 . 0 0 5
Induced erection 
(2)
931 2 0 0 . 0 6 4
Sired pregnancies 4 8 9 3 0.041
Response to Dietary Calcium Restriction Figure 6
Response to Dietary Calcium Restriction. TG females 
were more susceptible to bone loss in response to dietary 
calcium restriction. Female mice were analyzed using DEXA 
prior to and following dietary calcium restriction for 4 
weeks. The percent change from baseline for (A) Bone min-
eral density, (B) Bone mineral content, and (C) Bone area is 
shown. WT values are shown by open bars (n = 7) and TG (n 
= 8) by closed bars. Values represent the mean ± SEM. The 
level of significance is shown by asterisks: * P < 0.05, ** 0.001 
<P < 0.01, *** P < 0.001.
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of investigating the pleiotropic actions of TNFα by pheno-
typing the same mice in multiple in vivo assays confirms
the results of many studies conducted on different lines of
transgenic mice. Further, our results are consistent with an
interpretation that many of the effects of deregulated
TNFα expression are not directly a result of the develop-
ment of RA.
Mice expressing the hTNFα transgene driven by its endog-
enous promoter but containing the β-globin 3' flanking
region in place of hTNFα 3'sequences have previously
been described as a model for progressive arthritis [5,16].
The replacement of the endogenous 3' UTR of the hTNFα
gene with β-globin 3' sequences renders the gene non-
inducible in macrophages and also stabilizes the mRNA
in hematopoetic and stromal cells, leading to constitutive
expression of the transgene [16,24]. Consistent with these
studies, we demonstrated here that LPS treatment did not
induce expression of the transgene but inducibility of the
endogenous gene remained intact, as expected. Several
lines have been generated using this modified construct
[5] and common observations include progressive arthri-
tis and a wasting phenotype. In the most extensively stud-
ied line (TG197) both phenotypes are manifest by 4 to 6
weeks of age and early mortality is common [16]. This
rapid onset of arthritis and wasting may be attributable to
the relatively high circulating concentrations of hTNFα in
this line [18,23]. The hTNFα transgenic line studied here
was generated using the same construct as line TG197 but
expresses significantly lower levels of circulating hTNFα
and has a later onset of arthritis in addition to longer life
spans, which more closely models the disease progression
in humans. Therefore, this mouse line may provide a
more appropriate model for the pathophysiological effect
of increased levels of TNFα. One caveat that should be
pointed out in this model is that our transgene is likely
expressed principally in stromal cells, since it was previ-
ously shown that deletion of the 3'-region of the human
TNFα gene resulted in the loss of macrophage-specific
TNFα expression [16]. This pattern of expression may not
be consistent with all clinical pathologies associated with
increased TNFα levels.
Humans and mice both possess two receptors for TNFα,
TNFR1A (p55) and TNFR1B (p75) [25]. The generation of
knockout mice for both TNFR1A and TNFR1B, have iden-
tified specific roles for these two receptors. For example,
TNFR1B is required for TNF-induced T-cell toxicity and
tissue necrosis [26] but is not required for TNFα-mediated
lipolysis or inhibition of insulin-stimulated glucose trans-
port [27]. TNFR1A is thought to be the primary signaling
receptor on most cell types involved in resistance to bac-
terial infections and the lethal response to endotoxins
[15]. TNFR1A also inhibits the differentiation of adi-
pocytes, negatively affects lipid accumulation and insulin
sensitivity in mature adipocytes [27], and regulates leptin
production [28]. Additionally, TNFR1A mediates negative
effects on bone density [29], primarily by increasing the
number of osteoclast progenitors and stimulating their
differentiation and activity, but also by suppressing the
differentiation of osteoblasts. A species specificity was
demonstrated since human TNFα binds with high affinity
only to murine TNFR1A [25] thus, phenotypes identified
in this study should mainly reflect processes mediated by
TNFR1A.
The hTNFα TG mice in this study demonstrated sexual
dimorphisms in a number of physiological measures
despite similar levels of circulating hTNFα. The female TG
mice appeared less affected by the expression of the trans-
gene than the males. For example, significant differences
between the sexes were observed in the Irwin test, where
females were not phenotypically distinct from the WT
controls but age-matched males suffered reduced grip
strength and wire maneuver, likely as a result of the
advanced arthritis in the males (Table 3). TG males also
displayed a more pronounced decrease in body weight
and soft tissue composition than did the females (Figure
2; Table 4). While the basis for the sexual dimorphisms in
this TG line was not investigated, previous studies have
demonstrated that estrogen exerts a protective effect
against chronic exposure to hTNFα [30]. Significantly
fewer TNFR1A receptors in heart muscle of female mice
have also been reported although the liver and peripheral
white blood cells display equivalent numbers of TNFR1A
receptors [20]. It is unknown whether the density of this
receptor in females is also lower in other tissue types. By
14 weeks of age many male TG mice had already devel-
oped paw swelling and eritema consistent with moderate
arthritis, which is likely responsible for the observed phe-
notypes in the neurological tests in Irwin that were spe-
cific to the males (see [21] under "phenotype" for
supplemental data). There were no visible signs of arthri-
tis in age-matched females.
The dramatic decrease in BMD and BMC in the TG mice
of both sexes (see Results), and the accelerated bone loss
observed on a low calcium diet in the TG females (Figure
6) are consistent with the established role of TNFα in
bone resorption. A significant loss of BMD is also charac-
teristic of advanced RA [29,31-33].
Numerous studies have investigated the ability of TNFα to
modulate leptin expression and secretion. Acute adminis-
tration of LPS or relatively high levels of TNFα increase
leptin in both humans and mice [34-36]. However, low
levels of leptin have been measured in patients with both
chronic inflammatory conditions and cachexia [37-40],
raising the possibility that repression of leptin reflects bio-
logical compensation in response to these conditions. InBMC Physiology 2007, 7:13 http://www.biomedcentral.com/1472-6793/7/13
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addition to leptin's well established roles in inhibiting
food intake and increasing energy expenditure there is
also a growing body of evidence indicating that leptin can
regulate bone density, potentially through a central
hypothalamic response [41-43]. Thus, the results from
our comprehensive screen could be interpreted as a down-
regulation of leptin in an effort to reduce metabolic rate,
bone loss, and/or depletion of adipose stores. Alterna-
tively, suppression of circulating leptin may result from
chronic stimulation of receptor signaling pathways shared
with TNFα receptors.
Contradictory results describing effects of TNFα on glu-
cose tolerance and insulin sensitivity have been previ-
ously discussed [44,45]. In the TG mice described here
low circulating levels of TNFα did not significantly affect
glucose disposal in mice fed regular chow. However, the
TG mice did not develop impairments in insulin sensitiv-
ity and glucose tolerance like the WT mice did when fed
the HFD for 7 weeks. These findings are likely the result of
the blunted weight response of the TG mice to the HFD as
well as their maintenance of normal insulin levels.
The reduced body weights, altered soft tissue composi-
tion, and increased metabolic rate in the male TG mice
presented here are hallmarks of the cachectic state in
humans. Cachexia caused by arthritis, cancer and AIDS
have all been correlated with elevated TNFα levels [46].
Common observations include catabolic effects on body
mass with lean tissue, particularly skeletal muscle, more
affected than adipose stores [46-48]. An increased resting
metabolic rate is a frequent finding, and anorexia is found
in many but not all cases. In mice, a lethal wasting pheno-
type has been reported in animals expressing hTNFα
under the control of T-cell specific regulatory sequences
[17] and decreased body weight was observed in previ-
ously reported lines harboring the transgenic construct
used in this study [16]. In the phenotypic analysis of the
hTNFα TG mice presented here, the metabolic rate was
significantly elevated regardless of diet and both adipose
tissue and lean mass were significantly decreased. How-
ever, our results indicate that in this model, fat mass is
affected more than lean mass. In addition, the TG mice
did not display anorexic behavior since they consumed
comparable amounts of regular chow and were even
hyperphagic on the high-fat diet. However, the pro-
foundly decreased physical activity of the TG mice is con-
sistent with "sickness behavior" [49,50]. Despite the
obvious alterations in metabolic rate, body composition,
and body weight, these TG mice do not demonstrate
excessively early mortality. Male TG mice were main-
tained for over a year without obvious differences in sur-
vival compared to WT mice (unpublished observation).
These data suggest that the cachexia seen in RA may not be
directly caused by TNFα but the cytokine may be a con-
tributing factor and is responsible for many of the other
metabolic and physiological symptoms observed in rheu-
matoid cachexia as well as in our mouse model.
Although some of the phenotypes in male sexual behavior
in the hTNFα TG mice observed in this study were likely
due to arthritic-like lesions of the limbs and the compro-
mised health status of the animals we also showed that
the erectile function of the TG mice was decreased, which
is likely an additional factor contributing to the impair-
ment in male sexual behaviors. It has been proposed that
iNOS-mediated chronic NO overproduction in the penile
tissue could be a factor in declining erectile function asso-
ciated with aging and in Peyronie's disease in humans and
rat models [51,52]. A number of studies suggest that TNFα
activates iNOS mediated NO production in endothelial
and smooth muscle cells of blood vessels [53,54]. Sus-
tained up-regulation of iNOS may result in chronic over-
production of NO in the penile tissue of the hTNFα TG
mice and be eventually responsible for the impaired erec-
tile function of the mice observed in this study. The
reduced sexual activity of the TG mice likely contributed
to the decreased number of pregnancies sired by the TG
males compared to the WT controls observed in this
study. In addition, chronic exposure to the circulating
hTNFα might also affect the germ cell development and
sperm maturation in the TG males, as multiple effects of
TNFα on the biology of the testicular Sertoli cells were
reported in the literature [55-58].
Our results have confirmed many of the previously dem-
onstrated traits associated with constitutive expression of
TNFα. In addition, this study revealed several novel phys-
iological effects of TNFα such as the effects of TNFα on
induced erection and a sexual dimorphism of many of the
observed phenotypes. This study demonstrates a number
of divergent phenotypes in the same TG line and even the
same cohort of subjects, illustrating the pleiotropic role of
TNFα and the cross-physiological effects of cytokines such
as TNFα, which regulate or modulate immunological,
metabolic and nervous system processes.
Conclusion
In summary, our phenotypic analysis of the hTNFα TG
line demonstrates the utility of this mouse line as a model
for multiple human diseases in which chronically ele-
vated TNFα levels are present including its established use
in studies of RA. Chronic low levels of circulating hTNFα
resulted in defects in bone homeostasis, a hypermetabolic
state characterized by low body weight and hyperphagia
but coincident with low motor activity, depletion of adi-
pose tissue and lean mass, lack of a weight increase with a
HFD challenge, inappropriately low leptin levels and
impaired male sexual health. In addition, these studies
also revealed that a significant level of sexual dimorphismBMC Physiology 2007, 7:13 http://www.biomedcentral.com/1472-6793/7/13
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exists with respect to TNFα 's role in the progression and
severity of several biologically relevant phenotypes.
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